Ophthalmic Viscosurgical Devices Market - Global Forecast 2025-2030

The Ophthalmic Viscosurgical Devices Market size was estimated at USD 702.86 million in 2024 and expected to reach USD 765.93 million in 2025, at a CAGR 8.90% to reach USD 1,172.34 million by 2030.

Ophthalmic viscosurgical devices (OVDs) play a pivotal role in modern eye surgeries by providing the viscoelastic medium necessary for maintaining intraocular space and protecting delicate ocular tissues during intricate procedures. These transparent, gel-like formulations are injected into the anterior chamber of the eye to create and preserve the surgical field, minimizing tissue trauma and ensuring optimal visualization for surgeons. Their mechanical protection of corneal endothelial cells and stabilization of intraocular pressure during maneuvers such as phacoemulsification underscores their indispensability in cataract extractions and other anterior segment interventions. Transitional developments in OVD formulations have continually enhanced their safety and performance. For example, the approval of StableVisc and TotalVisc by the U.S. Food and Drug Administration in early 2023 introduced options with both cohesive and dispersive characteristics, augmenting chemical protection through unique scavenging agents and reinforcing mechanical barriers that reduce free radical damage during surgery.

The landscape of ophthalmic viscosurgical devices has been reshaped by a wave of technological breakthroughs and evolving surgical paradigms. The rise of viscoadaptive formulations that adjust their viscosity under shear stress has empowered surgeons with tools that seamlessly transition between cohesive and dispersive functions, delivering customized performance during phacoemulsification and intraocular lens implantation. This adaptability addresses the nuanced demands of both routine and complex procedures, fostering improved safety profiles and procedural efficiency. Simultaneously, advancements in phacoemulsification technology have driven a shift towards systems that optimize fluidics and intraocular pressure management. Active fluidics platforms, which maintain consistently low and physiologic intraoperative pressure, have been shown to reduce endothelial cell loss and postoperative inflammation, illustrating the synergy between device engineering and viscoelastic performance. Beyond fluidics, the integration of artificial intelligence, augmented reality, and three-dimensional visualization into the surgical environment is redefining procedural planning and execution, enhancing precision, and improving learning curves for surgeons worldwide.

In 2025, a series of U.S. tariff actions introduced new financial burdens across the medical device sector, directly affecting the supply chain for ophthalmic viscosurgical devices. Section 301 tariff increases on imports from China imposed duties as high as fifty percent on critical raw materials and components used in OVD manufacturing, while a parallel global ten percent levy on all goods entering the United States further exacerbated cost pressures for pharmaceutical excipients and packaging supplies. The Vision Council’s industry update underscored the compounding impact of these measures, reporting additional twenty percent duties on materials from China and extending duties on steel, aluminum, and specialty plastics crucial for OVD cannulas and prefilled syringes. Healthcare associations have cautioned that such escalated import costs risk shifting expenses downstream to providers and patients, potentially prompting manufacturers to reconsider global sourcing strategies or accelerate reshoring investments to maintain supply resilience and cost stability.

The product type segmentation of the OVD market reveals a spectrum of agents tailored to distinct surgical needs, encompassing cohesive viscoelastics prized for their ease of removal, dispersive solutions recognized for their capacity to coat intraocular structures, combined formulations that blend mechanical and chemical protective properties, and viscoadaptive options engineered to dynamically adapt their viscosity under surgical stress. Each category influences product development priorities, with cohesive agents favored for highviscosity stability and dispersive agents valued for targeted endothelial protection. Across compositions, the market differentiates between sodium hyaluronate, valued for its natural biocompatibility and receptor-mediated endothelial adherence; hydroxypropyl methylcellulose, a synthetic polymer offering controlled viscoelastic behavior and consistent rheological profiles; and combination blends that harness synergistic polymers to balance retention and viscosity-innovations that reflect an increasing emphasis on multifunctional performance and surgical precision. Applications of OVDs extend well beyond cataract surgery to encompass corneal transplantation, glaucoma procedures, and vitreoretinal interventions, each demanding tailored viscoelastic characteristics to maintain surgical space, preserve delicate tissues, and facilitate postoperative recovery. End user dynamics further segment the market, with highthroughput ambulatory surgery centers prioritizing ease of use and workflow compatibility, hospitals balancing product diversity with procurement efficiencies, and specialty ophthalmology clinics seeking advanced formulations for niche procedures. Distribution strategies layer on another dimension, spanning direct sales relationships that foster clinical partnerships, distributor networks that broaden geographic access, and emerging e-commerce channels enabling rapid fulfillment-underscoring the multifaceted segmentation structures that inform competitive positioning and go-to-market strategies.

In the Americas, widespread adoption of advanced cataract procedures and early regulatory approvals have positioned the United States as a hub for pioneering OVD innovations. U.S. surgeons benefit from expedited market entry of cohesive and dispersive formulations, while a robust ambulatory surgery center network drives demand for streamlined, highperformance viscoelastics. The FDA’s approval of new systems and ongoing clinical studies reinforce the region’s leadership in procedural safety and surgical efficiency. Within Europe, the Middle East & Africa, established healthcare infrastructures and premium intraocular lens programs have spurred growth in viscoadaptive and multifunctional OVDs. The CE Mark approval of Clareon Vivity IOLs in early 2025 highlights an advanced surgical landscape that increasingly incorporates extended depth of focus lenses, driving parallel demand for viscoelastics optimized for precision lens implantation and complex anterior segment workflows. Across the AsiaPacific region, rapid expansion of eye care services-fueled by demographic ageing, digitalhealth adoption, and government-led blindness elimination campaigns-has elevated the need for versatile viscoelastic solutions. In India, for example, demand surges driven by electronic device use and expanding eye center networks are prompting innovations in compact packaging and costeffective distribution, while regional professional conclaves spotlight collaborative efforts to standardize advanced cataract and refractive surgery techniques.

Prominent companies are strengthening their OVD portfolios through targeted product launches and strategic collaborations. Bausch + Lomb’s introduction of StableVisc and TotalVisc has underscored a dualaction approach to tissue protection, leveraging proprietary sorbitol chemistry for enhanced free radical scavenging alongside mechanical stability in cataract surgeries, reinforcing the company’s commitment to both clinician needs and patient safety. Alcon continues to lead with its Clareon Vivity platform, leveraging extended depth of focus IOL technology to drive demand for viscoelastics tailored to advanced lens implantation. The CE Mark approval and European rollout of Clareon Vivity in 2025 exemplifies Alcon’s strategy of integrating nextgeneration intraocular lenses with highperformance OVDs for comprehensive surgical solutions. Johnson & Johnson Vision’s expansion in the EMEA market, marked by the introduction of Tecnis PureSee lenses, complements a growing surgical ecosystem that prioritizes preloaded delivery systems and viscoelastic agents with optimized viscosity profiles. Similarly, Carl Zeiss Meditec’s emphasis on 3D visualization and digital integration at major industry meetings underscores a convergence of surgical imaging technologies and tailored viscoelastic solutions, illustrating how leading players are aligning viscoelastic development with broader surgical innovations.

To navigate evolving market dynamics, industry leaders should enhance the flexibility of their supply chains by diversifying sourcing strategies and evaluating in-region manufacturing opportunities to mitigate tariff impacts and ensure uninterrupted product availability. Collaborative engagement with trade associations and regulatory bodies can support targeted tariff exemptions for critical medical device components, preserving affordability for both providers and patients. Engaging in proactive advocacy and securing temporary exclusions for essential raw materials may offset cost escalations and sustain surgical affordability across healthcare systems. Simultaneously, prioritizing innovation in viscoelastic formulations-such as advancing multifunctional and sustainable polymers-and investing in digital health capabilities like surgical AI and workflow management tools will position companies at the forefront of surgeon preferences for efficiency and precision. Developing ecofriendly packaging solutions and minimizing waste in singleuse delivery systems can resonate with growing environmental stewardship initiatives in healthcare, differentiating offerings for hospital networks and ambulatory centers focused on sustainability. Finally, building strategic partnerships with regional clinical experts and leveraging omnichannel distribution models, from direct sales to e-commerce platforms, will accelerate market penetration in emerging AsiaPacific markets and support tailored product access. Structured field training programs and regional value-based service models can foster deeper clinician engagement, driving adoption of nextgeneration OVD offerings across diverse practice settings.

The research methodology underpinning this analysis combined comprehensive secondary research with primary interviews and expert consultations to ensure nuanced insights. Secondary sources included regulatory filings, peerreviewed clinical studies, and industry publications, alongside real-time trade news and association briefings to capture the latest regulatory and tariff developments. Primary investigations encompassed structured dialogues with key opinion leaders-encompassing ophthalmic surgeons, surgical center administrators, and supply chain specialists-to validate thematic shifts in surgical practice, assess viscoelastic preferences, and evaluate regional procurement strategies. Quantitative data were synthesized through cross-referenced clinical trial results, FDA approval documents, and demographic projections, while qualitative findings were distilled into strategic priorities through iterative expert review.

Ophthalmic viscosurgical devices have evolved into sophisticated surgical adjuncts that underpin the safety and efficacy of a wide range of anterior and posterior segment procedures. As demographic shifts drive escalating demand for cataract, glaucoma, and vitreoretinal interventions-and as surgical technologies continue to advance-OVDs must adapt to deliver precision, versatility, and efficiency across diverse clinical settings. Transformative trends in viscoadaptive formulations, fluidics optimization, digital integration, and sustainability are redefining market expectations, placing a premium on collaborative innovation, agile supply chains, and clinician partnerships. By leveraging comprehensive segmentation insights and embracing targeted regional strategies, stakeholders can steer product development and distribution priorities to align with evolving surgeon requirements and patient needs across global markets. Ultimately, the convergence of clinical excellence, regulatory agility, and strategic foresight will shape the trajectory of the OVD landscape, empowering industry leaders to drive surgical performance and deliver meaningful patient outcomes in the years ahead.

Ready to dive deeper and capitalize on these critical insights, industry leaders can take the next step by securing the full market research report. Reach out to Ketan Rohom, Associate Director of Sales & Marketing, to obtain a tailored briefing, access exclusive data sets, and discuss how these findings can empower your strategic decisions. Connect with Ketan to unlock comprehensive analysis, customized consulting options, and begin shaping your path to a leading market position.